What is the reason to delay launching the SGLT-2 inhibitor type diabetes treatment?

Published: 2015-01-16 09:25:01

Updated: 2015-01-16 09:25:01

Boehringer Ingelheim and Lilly decided to delay launching the diabetes treatment ‘Jardiance’ in the market.

According to the industry concerned on the 15^th, Boehringer Ingelheim and Lilly (hereinafter referring to BI·Lilly) has halted on the launching procedure of the SGLT-2 inhibitor ‘Jardiance (empagliflozin)’, which has also been known as the weight-losing diabetes treatment.

Here is the m...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.